Journal of Hepatology
Volume 53, Issue 2 , Pages 283-290 , August 2010

Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis

  • Florence Wong

      Affiliations

    • Department of Medicine, University of Toronto, Canada
    • Corresponding Author InformationCorresponding author. Address: 9th floor, North Wing, Room 983, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario, Canada M5G2C4. Tel.: +1 416 340 3834; fax: +1 416 340 5019.
    • ,
  • Pere Gines

      Affiliations

    • Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), CIBER de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Catalunya, Spain
    • ,
  • Hugh Watson

      Affiliations

    • Internal Medicine, Clinical Development, Sanofi-Aventis R&D, Chilly-Mazarin, France
    • ,
  • Yves Horsmans

      Affiliations

    • Saint-Luc University Hospital, Brussels, Belgium
    • ,
  • Paolo Angeli

      Affiliations

    • University of Padova, Italy
    • ,
  • Paul Gow

      Affiliations

    • Austin Hospital, University of Melbourne, Australia
    • ,
  • Pascal Minini

      Affiliations

    • Internal Medicine, Clinical Development, Sanofi-Aventis R&D, Chilly-Mazarin, France
    • ,
  • Mauro Bernardi

      Affiliations

    • Department of Internal Medicine, University of Bologna, Italy

Received 17 January 2010 ,Revised 22 February 2010 ,Accepted 23 February 2010.

References 

  1. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–231
  2. Planas R, Montoliu S, Balleste B, Rivera M, Miquel M, Masnou H, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385–1394
  3. Moreau R, Delegue P, Pessione F, Hillaire S, Durand F, Lebrec D, et al. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver Int. 2004;24:457–464
  4. Moore KP, Wong F, Gines P, Ochs A, Bernardi M, Salerno F, et al. The management of ascites – report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258–266
  5. Gines P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology. 1987;93:234–241
  6. Salerno F, Badalamenti S, Incerti P, Tempini S, Restelli B, Bruno S, et al. Repeated paracentesis and i.v. albumin infusion to treat ‘tense’ ascites in cirrhotic patients. A safe alternative therapy. J Hepatol. 1987;5:102–108
  7. Wong F. The use of TIPS in chronic liver disease. Ann Hepatol. 2006;5:5–15
  8. Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124:933–939
  9. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182–191
  10. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151–2159
  11. Ginès P, Wong F, Watson H, Milutinovic S, Ruiz del Arbol L, Olteanu D, et al. Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium concentration in patients with cirrhosis and hyponatremia. Hepatology. 2008;48:204–213
  12. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT, et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–721
  13. Lawless JF, Nadeau C. Some simple robust method for the analysis of recurrent events. Technometrics. 1995;37:158–168
  14. Cárdenas A, Arroyo V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab. 2003;17:607–622
  15. Bonilla-Felix M. The development of water transport in the collecting duct. Am J Physiol. 2004;287:F1093–F1101
  16. Shear L, Ching S, Gabuzda GJ. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med. 1970;282:1391–1396
  17. Bankir L, Fernandes S, Bardoux P, Bouby N, Bichet DG. Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J Am Soc Nephrol. 2005;16:1920–1928
  18. Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol. 2008;19:1721–1731
  19. Bertuccio CA, Ibarra FR, Toledo JE, Arrizurieta EE, Martin RS. Endogenous vasopressin regulates Na–K–ATPase and Na(+)–K(+)–Cl(−) cotransporter rbsc-1 in rat outer medulla. Am J Physiol Renal Physiol. 2002;282:F265–F270
  20. Rozansky DJ. The role of aldosterone in renal sodium transport. Semin Nephrol. 2006;26:173–181
  21. Giebisch G. Renal potassium transport: mechanisms and regulations. Am J Physiol. 1998;274:F817–F833

☆ The study was registered on a public clinical trial registry website, www.ClinicalTrials.org, number NCT 00501384.

PII: S0168-8278(10)00381-8

doi: 10.1016/j.jhep.2010.02.036

Journal of Hepatology
Volume 53, Issue 2 , Pages 283-290 , August 2010

Article Tools

* Image Usage & Resolution